ACE and coronary artery disorder: In addition, most of the patients in the CAD group and non-CAD group received antiagregant medication (59% vs 51%), angiotensin-converting enzyme inhibitor (ACE-I) (59% vs 54%), Beta-Bloquers (50% vs 51%), fibrate (32% vs 20%) and statins medication (31% vs 41%).